Half Your Clinical Data Is Going Unanalyzed
Half of all clinical trial data goes unanalyzed. The pharmaceutical industry generates petabytes of formulation-relevant intelligence that never informs development decisions - a systematic blind spot that AI is finally positioned to exploit.
The Unanalyzed Half
ClinicalTrials.gov now holds over 500,000 registered studies, built over 25 years of clinical evidence collection backed by billions in investment and millions of patient-years of exposure data. Roughly half of this clinical trial data remains unanalyzed. Not because it is proprietary or restricted, but because nobody has examined it.
The problem is extraction, not storage or access. Data sits in disparate formats, buried in unstructured text, scattered across silos with no cross-communication. Phase 3 trials now generate 3.6 million data points on average, triple the volume from a decade ago. Analytical capacity has not kept pace.
For formulation scientists, those unanalyzed datasets contain answers to concrete questions: why certain formulations failed, which excipient combinations triggered adverse events, what processing parameters correlate with clinical success. The data is there. The extraction tools are now mature enough to get at it.
The Silo Problem
"GSK maintains 8 petabytes of clinical trial data distributed across 2,100 separate data silos, each with its own format, governance structure, and access protocols."
Source: Industry Analysis of Pharmaceutical Data Infrastructure
The Failed Trial Graveyard
The pharmaceutical industry runs at a 90% clinical trial failure rate. Nine out of ten development programmes generate extensive data on what does not work, and this negative knowledge rarely leaves the originating company.
IGF1R inhibitors illustrate the cost of this information gap. Between 2005 and 2015, pharmaceutical companies spent an estimated $1.6-2.3 billion developing 16 different IGF1R inhibitors across 183 clinical trials. None were approved. Companies repeated the same mistakes because trial data stayed locked in proprietary silos, invisible to competitors working on identical targets.
Failed trials hold formulation intelligence that successful trials cannot: which delivery systems caused unexpected toxicity, which bioavailability approaches fell short, which patient populations tolerated specific dosage forms poorly. This negative knowledge has direct value for formulators, and it remains inaccessible to the scientists who need it.
90%
Clinical Trial Failure Rate
3.6M
Data Points per Phase 3 Trial
$2.3B
Wasted on IGF1R Failures
2,100
Data Silos at GSK Alone
The Formulation-Clinical Disconnect
Formulation scientists work with dissolution profiles, excipient compatibility, and manufacturing parameters. Clinical researchers track efficacy endpoints, adverse events, and patient outcomes. The two disciplines rarely intersect in any structured way, even though formulation decisions directly drive clinical results.
Part of the barrier is structural: clinical data lives in EDC systems while formulation data sits in LIMS, with no shared data model between them. Part is cultural: formulation scientists train to optimize in vitro performance, not to query clinical databases for in vivo correlations.
Format Incompatibility:
Clinical trial data is captured in CRF structures built for regulatory submission, not formulation analysis. Pulling excipient-related adverse events out of these records means manual cross-referencing across multiple data sources.
Lack of Formulation Metadata:
Trial registrations rarely include detailed formulation specifications. A study might report "oral tablet" without documenting the coating system, disintegrant, or processing method. These are the variables that govern clinical performance, and they go unrecorded.
Organizational Silos:
Formulation development sits within CMC groups, walled off from clinical operations. The scientists who design dosage forms rarely see the clinical data those forms generate. The feedback loop stays open.
The Untapped Data Landscape
Beyond the 500,000+ studies in ClinicalTrials.gov, several public data sources contain formulation-relevant intelligence that most development teams never tap in any organized way. Each database covers different ground; combined, they form a usable intelligence infrastructure.
FAERS: Post-Market Formulation Signals
The FDA Adverse Event Reporting System holds 28+ million reports, with 2+ million new submissions each year. FAERS data on excipient-related adverse events, formulation-specific tolerability patterns, and route-of-administration signals offers real-world evidence that controlled trials do not capture.
28M+ reports
1969-present
Free API access
DailyMed: Structured Label Intelligence
Over 154,000 drug labels in machine-readable SPL format, covering formulation compositions, inactive ingredient lists, storage conditions, and clinical pharmacology data. No other public source matches it for breadth of approved formulation specifications.
154K+ labels
SPL format
Daily updates
Patent Literature: Hidden Formulation Insights
Patent applications disclose detailed experimental data absent from peer-reviewed literature: failed approaches, comparative excipient studies, and stability data that competitors spent millions generating. Formulation scientists can use this negative knowledge to avoid repeating costly dead ends.
Experimental data
Failed approaches
Comparative studies
AI-Powered Pattern Extraction
Current NLP and machine learning methods have turned the clinical data problem from an access issue into an extraction problem. AI now processes the unstructured text that makes up most clinical trial records (protocol documents, adverse event narratives, investigator reports) and pulls out formulation-relevant findings at scale.
Published studies show AI models predicting clinical trial success at 83-89% accuracy, against 56-70% for conventional prediction methods. This improvement comes from pattern identification across thousands of trials, catching correlations between formulation characteristics and clinical outcomes that manual review cannot surface at comparable volume.
NLP for Unstructured Text
Pull formulation insights from clinical study reports, adverse event narratives, and regulatory correspondence trapped in free-text format.
83-89% Prediction Accuracy
Pattern Recognition
Surface correlations between formulation variables and clinical outcomes across hundreds of trials that manual review cannot detect at scale.
Cross-Trial Analysis
"AI models achieve 83-89% accuracy in predicting clinical trial success, versus 56-70% for traditional methods. That gap translates into fewer failed programmes and shorter development timelines."
Source: Analysis of AI-Augmented Clinical Trial Prediction
Practical Applications for Formulation Science
Turning clinical data into formulation decisions requires analytical approaches built for the specific constraints of dosage form development:
1
Excipient Safety Signal Detection:
Query FAERS for adverse events linked to specific inactive ingredients. Flag excipient combinations associated with hypersensitivity, GI intolerance, or injection site reactions before incorporating them into new formulations.
2
Bioavailability Correlation Analysis:
Map clinical PK data against formulation parameters across similar compounds. Determine which dosage form characteristics track with successful absorption enhancement and which approaches consistently fall short.
3
Failure Mode Learning:
Analyze terminated trials to understand why specific formulation approaches failed in patients. Turn competitors' expensive failures into your design constraints.
4
Patient Population Optimization:
Map how formulation characteristics interact with patient demographics, comorbidities, and concomitant medications. Design dosage forms matched to the populations that will use them.
5
Competitive Formulation Intelligence:
Track trial registrations to anticipate competitors' formulation strategies. Spot gaps where alternative dosage forms could deliver clinical differentiation.
DeepC's Analytical Capabilities
DeepC Analytics and Research Agent are built to extract formulation intelligence from clinical data sources. The platform connects ClinicalTrials.gov, FAERS, DailyMed, and patent literature in a unified knowledge graph, enabling queries that no single database can answer on its own.
Cross-Source Correlation
Link trial outcomes to formulation parameters across databases
NLP Extraction Pipeline
Mine unstructured text for formulation-relevant insights
Predictive Modeling
Forecast clinical success based on formulation characteristics
The Prediction Gap
56-70%
83-89%
Clinical trial success prediction accuracy
Data Growth Trajectory
3x
Increase in Phase 3 trial data points over the past decade. Current trials generate 3.6 million data points on average, outpacing what traditional analytical workflows can handle.
Exponential Complexity
Strategic Implications
Clinical data is equally available to every company, but the ability to extract value from it is not. Organizations that invest in data extraction infrastructure will outperform those that continue treating clinical databases as static reference material rather than operational intelligence.
For formulation scientists, this changes how work gets done. The field has long been empirical: test combinations until something works. Clinical data intelligence makes predictive formulation possible, designing dosage forms informed by patterns drawn from thousands of prior clinical outcomes.
De-Risk Early
Spot formulation failure modes in historical trial data before committing to development paths that others have already tried and abandoned.
Optimize Faster
Apply pattern recognition across similar compounds to narrow the design space before committing to expensive bench work.
Differentiate Clinically
Build formulations that address unmet needs found through structured analysis of adverse event profiles and tolerability data.
Mining the Goldmine
Half of all clinical trial data sits unanalyzed today. That will not last. AI extraction is maturing, and organizations are starting to treat clinical data as a strategic asset rather than an archive. The competitive question is timing.
The 90% clinical trial failure rate is not a fixed constant of pharmaceutical development. It reflects, in part, the cost of developing drugs without drawing on the collective record of prior failures. Organizations that mine that record will reduce their own failure rates.
The data is available. The extraction tools are production-ready. What remains is the decision to use them.